Kendall Square has become a hub of biotech innovation and a popular location for up and coming life sciences firms. Now, a ...

Biogen's new management is diversifying its ... the unsuccessful launch and commercial failure of new drugs, in particular Aduhelm. This product has faced skepticism from the medical community ...

The global neurology clinical trials market is poised for substantial growth over the next decade, with projections forecasting an increase in market size from USD 5.7 billion in 2022 to a remarkable ...

Biogen’s pivot towards a more collaborative R&D model and its implications for the company’s pipeline and commercial strategy reflect a broader trend within the pharmaceutical industry to ...

Biogen’s pivot towards a more collaborative R&D model and its implications for the company’s pipeline and commercial strategy reflect a broader trend within the pharmaceutical industry to leverage ...

Boston commercial developer Mark Tang called the joint project a “very rare opportunity” both for MIT and for a company like Biogen looking to occupy a prime location in Kendall Square ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...

Spanning approximately 580,000-square-feet, the facility will integrate Biogen’s R&D and technical operations teams together with its global and North American commercial organisations. It is ...